State Street
BCYC

State Street’s Bicycle Therapeutics BCYC Stock Holding History

State Street’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$131K Buy
30,829
+317
+1% +$1.45K ﹤0.01% 3930
2026
Q1 		$142K Sell
30,512
-39,666
-57% -$227K ﹤0.01% 3967
2025
Q4 		$497K Sell
70,178
-4,227
-6% -$31.2K ﹤0.01% 3679
2025
Q3 		$576K Buy
74,405
+8,408
+13% +$63.5K ﹤0.01% 3631
2025
Q2 		$459K Sell
65,997
-19,656
-23% -$157K ﹤0.01% 3632
2025
Q1 		$727K Sell
85,653
-2,112
-2% -$24.9K ﹤0.01% 3504
2024
Q4 		$1.23M Buy
87,765
+1,494
+2% +$32K ﹤0.01% 3442
2024
Q3 		$1.95M Buy
86,271
+60,399
+233% +$1.39M ﹤0.01% 3337
2024
Q2 		$524K Hold
25,872
– – ﹤0.01% 3559
2024
Q1 		$644K Sell
25,872
-3,694
-12% -$78.5K ﹤0.01% 3582
2023
Q4 		$535K Sell
29,566
-6,300
-18% -$104K ﹤0.01% 3625
2023
Q3 		$721K Buy
35,866
+27,200
+314% +$622K ﹤0.01% 3599
2023
Q2 		$221K Buy
+8,666
New +$201K ﹤0.01% 3976
2023
Q1 		– Sell
-8,861
Closed -$262K – 4791
2022
Q4 		$262K Buy
8,861
+39
+0.4% +$1.05K ﹤0.01% 4007
2022
Q3 		$205K Sell
8,822
-8,652
-50% -$206K ﹤0.01% 4131
2022
Q2 		$293K Buy
17,474
+6,787
+64% +$143K ﹤0.01% 4040
2022
Q1 		$469K Buy
10,687
+2,333
+28% +$109K ﹤0.01% 4076
2021
Q4 		$509K Buy
8,354
+1,654
+25% +$91.3K ﹤0.01% 4016
2021
Q3 		$279K Buy
+6,700
New +$234K ﹤0.01% 4229

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

State Street's BCYC Position: Q2 2026 in Review

State Street increased its Bicycle Therapeutics (BCYC) stake by 1% in Q2 2026, buying an estimated $1.45K and bringing the position to 30,829 shares worth $131K. The position accounts for ﹤0.01% of the portfolio, ranked #3930.

State Street first reported a position in BCYC in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.95M in Q3 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • State Street held 30,829 shares of Bicycle Therapeutics worth $131K as of Q2 2026.
  • State Street bought 317 Bicycle Therapeutics shares in Q2 2026, an estimated $1.45K.
  • Bicycle Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3930 holding.
  • State Street first reported a position in Bicycle Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • State Street's Bicycle Therapeutics position peaked at $1.95M in Q3 2024.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.